Tags

Type your tag names separated by a space and hit enter

Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
Diagn Microbiol Infect Dis. 2008 Feb; 60(2):185-92.DM

Abstract

The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Program is a longitudinal antimicrobial surveillance study that has been in place since 1997 in centers that are actively prescribing meropenem. This report examines the activity of meropenem and other broad-spectrum antibacterial comparators against the 7124 isolates submitted by 40 European centers during 2006 and compares the results with those obtained in 2002. Cumulative susceptibility rates against all methicillin-susceptible staphylococci were amikacin (99.2%) > meropenem and imipenem (98.1%) > piperacillin + tazobactam (96.6%) > gentamicin (91.8%) > tobramycin (91.1%) > ciprofloxacin (83.1%) > ceftazidime (59.7%). Against all species of Enterobacteriaceae, the rates were meropenem (98.9%) > imipenem (97.9%) > amikacin (97.1%) > gentamicin (91.0%) > piperacillin + tazobactam (83.4%) > ceftazidime (82.3%) > ciprofloxacin (82.2%) > tobramycin (75.1%). The carbapenems were also the most effective class against nonfermenters, although there are increasing numbers of multidrug-resistant (MDR)-Acinetobacter spp. being reported. Overall meropenem is still retaining excellent activity against the majority of isolates studied. The continued need for surveillance studies such as MYSTIC in order that correct clinical decisions concerning antibiotic selection are made is once again demonstrated.

Authors+Show Affiliations

Infection Discovery Department, AstraZenca, Alderley House, Alderley Park, Macclesfield, SK10 4TG Cheshire, UK. philip.turner@astrazeneca.com

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

17945455

Citation

Turner, Philip J.. "Meropenem Activity Against European Isolates: Report On the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 Results." Diagnostic Microbiology and Infectious Disease, vol. 60, no. 2, 2008, pp. 185-92.
Turner PJ. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagn Microbiol Infect Dis. 2008;60(2):185-92.
Turner, P. J. (2008). Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. Diagnostic Microbiology and Infectious Disease, 60(2), 185-92.
Turner PJ. Meropenem Activity Against European Isolates: Report On the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 Results. Diagn Microbiol Infect Dis. 2008;60(2):185-92. PubMed PMID: 17945455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results. A1 - Turner,Philip J, Y1 - 2007/10/18/ PY - 2007/07/09/received PY - 2007/08/13/revised PY - 2007/09/10/accepted PY - 2007/10/20/pubmed PY - 2008/4/11/medline PY - 2007/10/20/entrez SP - 185 EP - 92 JF - Diagnostic microbiology and infectious disease JO - Diagn. Microbiol. Infect. Dis. VL - 60 IS - 2 N2 - The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) Program is a longitudinal antimicrobial surveillance study that has been in place since 1997 in centers that are actively prescribing meropenem. This report examines the activity of meropenem and other broad-spectrum antibacterial comparators against the 7124 isolates submitted by 40 European centers during 2006 and compares the results with those obtained in 2002. Cumulative susceptibility rates against all methicillin-susceptible staphylococci were amikacin (99.2%) > meropenem and imipenem (98.1%) > piperacillin + tazobactam (96.6%) > gentamicin (91.8%) > tobramycin (91.1%) > ciprofloxacin (83.1%) > ceftazidime (59.7%). Against all species of Enterobacteriaceae, the rates were meropenem (98.9%) > imipenem (97.9%) > amikacin (97.1%) > gentamicin (91.0%) > piperacillin + tazobactam (83.4%) > ceftazidime (82.3%) > ciprofloxacin (82.2%) > tobramycin (75.1%). The carbapenems were also the most effective class against nonfermenters, although there are increasing numbers of multidrug-resistant (MDR)-Acinetobacter spp. being reported. Overall meropenem is still retaining excellent activity against the majority of isolates studied. The continued need for surveillance studies such as MYSTIC in order that correct clinical decisions concerning antibiotic selection are made is once again demonstrated. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/17945455/Meropenem_activity_against_European_isolates:_report_on_the_MYSTIC__Meropenem_Yearly_Susceptibility_Test_Information_Collection__2006_results_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(07)00393-8 DB - PRIME DP - Unbound Medicine ER -